AI assistant
Vaxcyte, Inc. — Director's Dealing 2025
Aug 30, 2025
31100_dirs_2025-08-29_e612b24c-c33b-4751-9b3c-2b501e4a095f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-08-29
Reporting Person: Cowan Elvia (SVP, FINANCE)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-07 | Common Stock | A | 2810 | — | Acquired | 27205 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-08-29 | Stock Option (right to buy) | $30.79 | A | 9743 | Acquired | 2035-08-29 | Common Stock (9743) | Direct |
Footnotes
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on March 7, 2026 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2: Includes 289 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.
F3: 1/48 of shares subject to the option vest on September 29, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.